1 Ocak 2021 Dergi makalesi Açık Erişim

Karakus, Gozde Sir; Tastan, Cihan; Kancagi, Derya Dilek; Yurtsever, Bulut; Tumentemur, Gamze; Demir, Sevda; Turan, Raife Dilek; Abanuz, Selen; Cakirsoy, Didem; Seyis, Utku; Ozer, Samed; Elibol, Omer; Elek, Muhammer; Ertop, Gurcan; Arbale, Serap; Elmas, Merve Acikel; Hermsinlioglu, Canso; Kocagoz, Ayse Sesin; Ng, Ozden Hatirnaz; Akyoney, Sezer; Akyoney, Sezer

Dublin Core

<?xml version='1.0' encoding='utf-8'?>
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Karakus, Gozde Sir</dc:creator>
  <dc:creator>Tastan, Cihan</dc:creator>
  <dc:creator>Kancagi, Derya Dilek</dc:creator>
  <dc:creator>Yurtsever, Bulut</dc:creator>
  <dc:creator>Tumentemur, Gamze</dc:creator>
  <dc:creator>Demir, Sevda</dc:creator>
  <dc:creator>Turan, Raife Dilek</dc:creator>
  <dc:creator>Abanuz, Selen</dc:creator>
  <dc:creator>Cakirsoy, Didem</dc:creator>
  <dc:creator>Seyis, Utku</dc:creator>
  <dc:creator>Ozer, Samed</dc:creator>
  <dc:creator>Elibol, Omer</dc:creator>
  <dc:creator>Elek, Muhammer</dc:creator>
  <dc:creator>Ertop, Gurcan</dc:creator>
  <dc:creator>Arbale, Serap</dc:creator>
  <dc:creator>Elmas, Merve Acikel</dc:creator>
  <dc:creator>Hermsinlioglu, Canso</dc:creator>
  <dc:creator>Kocagoz, Ayse Sesin</dc:creator>
  <dc:creator>Ng, Ozden Hatirnaz</dc:creator>
  <dc:creator>Akyoney, Sezer</dc:creator>
  <dc:creator>Akyoney, Sezer</dc:creator>
  <dc:date>2021-01-01</dc:date>
  <dc:description>COVID-19 outbreak caused by SARS-CoV-2 created an unprecedented health crisis since there is no vaccine for this novel virus. Therefore, SARS-CoV-2 vaccines have become crucial for reducing morbidity and mortality. In this study, in vitro and in vivo safety and efficacy analyzes of lyophilized vaccine candidates inactivated by gamma-irradiation were performed. The candidate vaccines in this study were OZG-3861 version 1(V1), an inactivated SARS-CoV-2 virus vaccine, and SK-01 version 1 (V1), a GM-CSF adjuvant added vaccine. The candidate vaccines were applied intradermally to BALB/c mice to assess toxicity and immunogenicity. Preliminary results in vaccinated mice are reported in this study. Especially, the vaccine models containing GM-CSF caused significant antibody production with neutralization capacity in absence of the antibody-dependent enhancement feature, when considered in terms of T and B cell responses. Another important finding was that the presence of adjuvant was more important in T cell in comparison with B cell response. Vaccinated mice showed T cell response upon restimulation with whole inactivated SARS-CoV-2 or peptide pool. This study shows that the vaccines are effective and leads us to start the challenge test to investigate the gamma-irradiated inactivated vaccine candidates for infective SARS-CoV-2 virus in humanized ACE2+ mice.</dc:description>
  <dc:identifier>https://aperta.ulakbim.gov.trrecord/231896</dc:identifier>
  <dc:identifier>oai:aperta.ulakbim.gov.tr:231896</dc:identifier>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:rights>http://www.opendefinition.org/licenses/cc-by</dc:rights>
  <dc:source>SCIENTIFIC REPORTS 11(1)</dc:source>
  <dc:title>Preclinical efficacy and safety analysis of gamma-irradiated inactivated SARS-CoV-2 vaccine candidates</dc:title>
  <dc:type>info:eu-repo/semantics/article</dc:type>
  <dc:type>publication-article</dc:type>
</oai_dc:dc>